Small molecule inhibitor combination treatment effectively represses global B-cell signaling in diffuse large B-cell lymphoma
Melde WitmondiD, Babet Bollen, Pam Heijmans, Annemiek B. van SprieliD, Jessie A.G.L. van BuggenumiD, Wilhelm T. S. HuckiD
Abstract
Cells sense their environment via signaling networks and malignant cells often hijack signaling pathways for their growth, which complicates defining the effects of drugs. Here, we map the state of the signaling network of B-cell lymphoma cells via simultaneous quantification of 111 (phospho-)proteins. We demonstrate that the B-cell signaling network can be disrupted with specific clinical small molecule inhibitors (iBTK, iSYK, iNF{kappa}B), thereby inducing a repressed state of the network. Principal component analysis identifies how the three inhibitors work along subtly different repression axes through the signaling state landscape. Finally, we observe that 1 {micro}M combination treatment with all three inhibitors is more effective in inducing the repressed state than 10 {micro}M of the single inhibitors. These results emphasize that cellular signaling occurs in complex networks, and underscore how quantification of the signaling state landscape provides insights into how combination drug treatments can bring cells in a desired network state.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A virtual B cell lymphoma model to predict effective combination therapy
Wei Du, Rebecca Goldstein, … Olivier Elemento·bioRxiv·Jan 18, 2016
- Quantitative modelling of signaling in aggressive B cell lymphoma unveils conserved core network
Bertram Klinger, Isbael Rausch, … Dieter Kube·bioRxiv·Mar 25, 2024
- Pre-Clinical Blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.
C. Vincent-Fabert, L. Roland, … N. Faumont·bioRxiv·Dec 21, 2018
- Overcoming ibrutinib resistance by targeting phosphatidylinositol-3-kinase signaling in diffuse large B-cell lymphoma
N. Jain, O. Havranek, … L. Sehgal·bioRxiv·Jan 28, 2019
- Targeting Aberrant FGFR Signaling with Infigratinib Enhances the Efficacy of BTK/PI3K Inhibitors and Bendamustine in Lymphoma Cells
Giulio Sartori, Alessandro Ghiringhelli, … Francesco Bertoni·bioRxiv·Dec 25, 2025
- Distinct Response Patterns to PHB Modulators in B Cell Lymphoma Models
Christoph Schultheiß, Maja Kadel, … Mascha Binder·bioRxiv·Jun 12, 2025